CAPTIVATE: Primary Analysis From the Fixed-Duration Cohort of First-line Ibrutinib + Venetoclax for CLL/SLL

June 4-8, 2021; Online at https://conferences.asco.org/am
In patients with previously untreated CLL/SLL, fixed-duration treatment of ibrutinib plus venetoclax resulted in deep and durable responses with high rates of treatment completion.
Format: Microsoft PowerPoint (.ppt)
File Size: 409 KB
Released: June 11, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AbbVie
AstraZeneca
Bristol-Myers Squibb
GlaxoSmithKline
Novartis Pharmaceuticals Corporation
Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc.
Sanofi Genzyme

Related Content

Global perspective of key studies presented at ASCO, EHA, ICML 2021 from an international expert in CLL from Clinical Care Options (CCO)

George Follows, BM, BCh, PhD Released: September 17, 2021

Analysis of key studies in hematologic malignancies from ASCO 2021 presented by Drs. Ian Flinn, Shaji Kumar, and Eunice Wang, as reported by Clinical Care Options (CCO)

Ian W. Flinn, MD, PhD Shaji K. Kumar, MD Eunice S. Wang, MD Physicians: maximum of 1.25 AMA PRA Category 1 Credits Released: September 13, 2021 Expired: September 12, 2022

Download this summary on the management of adverse events associated with BTK inhibitors, from Clinical Care Options (CCO).

Beth Faiman, PhD, MSN, APRN-BC, AOCN person default Amy Goodrich, RN, MSN, CRNP-AC Sandra E. Kurtin, PhD, ANP-C, AOCN Released: September 10, 2021

On-demand webcast on the current treatment paradigm in mantle cell lymphoma featuring 3 faculty experts presented by Clinical Care Options (CCO)

Julie M. Vose, MD, MBA
Program Director
Christopher R. Flowers, MD, MS John P. Leonard, MD
Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: September 7, 2021 Expired: September 6, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue